Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients.

Liu, Kaiyan; Stern, Sydney; Heil, Emily L; Li, Linhao; Khairi, Rula; Heyward, Scott; Wang, Hongbing

Liu, Kaiyan; Stern, Sydney; Heil, Emily L; Li, Linhao; Khairi, Rula; Heyward, Scott; Wang, Hongbing.

Afiliación

Liu K; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Stern S; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Heil EL; Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Li L; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Khairi R; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Heyward S; BioIVT, 1450 S Rolling Rd, Halethorpe, Maryland, USA.
Wang H; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Hepatol Commun ; 7(3): e0034, 2023 03 01.

Article en En | MEDLINE | ID: mdl-36809346

Asunto(s)

COVID-19; Enfermedad Hepática Inducida por Sustancias y Drogas; Humanos; Tratamiento Farmacológico de COVID-19; Hepatocitos; Dexametasona

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Hepática Inducida por Sustancias y Drogas / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hepatol Commun Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google